SCHEMBL7142628

SCHEMBL7142628

COc1ccc(OC)c(S(=O)(=O)N(CCc2ccccc2)C2CCN(Cc3ccccc3)CC2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.62
ALDH1A1 P00352 7/20 0.54
KDM4E B2RXH2 2/20 0.54
MEN1 O00255 2/20 0.54
MAPK1 P28482 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
SIGMAR1 Q99720 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
CCR3 P51677 1/20 0.47
CHRM2 P08172 1/20 0.47
CHRM3 P20309 1/20 0.47
PKM P14618 1/20 0.47
POLB P06746 2/20 0.47
OPRM1 P35372 1/20 0.46
DRD2 P14416 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148472 0.84 KMT2A (0.64) KMT2AALDH1A1KDM4EMEN1MAPK1
SCHEMBL7142813 0.78 HTR2A (0.56) KMT2AMEN1SIGMAR1CHRM2CHRM3
SCHEMBL7141098 0.75 OPRM1 (0.53) KMT2AALDH1A1MEN1SMN1; SMN2CHRM2
SCHEMBL3811083 0.74 CTSL (0.56) KMT2AALDH1A1MAPK1SMN1; SMN2CYP3A4
SCHEMBL7141347 0.74 CHRM4 (0.52) KMT2AMEN1SMN1; SMN2CHRM2CHRM3
SCHEMBL7141075 0.74 HTT (0.56) ALDH1A1SIGMAR1CYP2D6CHRM2CHRM3
SCHEMBL7148857 0.74 MEN1 (0.56) KMT2AALDH1A1MEN1SIGMAR1L3MBTL1
SCHEMBL3808146 0.73 GAA (0.47) KMT2AALDH1A1MEN1MAPK1NPSR1
SCHEMBL16757355 0.72 KMT2A (0.67) KMT2AALDH1A1KDM4EMEN1MAPK1
SCHEMBL7167334 0.72 ALDH1A1 (0.52) KMT2AALDH1A1KDM4EMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 KMT2A 1833/4885ALDH1A1 1218/4885KDM4E 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.